Science 15 January 1993: Vol. 259. no. 5093, pp. 368 - 370 DOI: 10.1126/science.7678351

Prev | Table of Contents | Next

Articles

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.

L. Zhang, T. F. Gajewski, and J. Kline (2009)
Blood 114, 1545-1552
 |  Abstract »  |  Full Text »  |  PDF »

The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation.

J. D. Wolchok and Y. Saenger (2008)
Oncologist 13, 2-9
 |  Abstract »  |  Full Text »  |  PDF »

Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma.

H. Nishida, H. Tsuchiya, and K. Tomita (2008)
J Bone Joint Surg Br 90-B, 1249-1255
 |  Abstract »  |  Full Text »  |  PDF »

Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma.

J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski (2008)
Clin. Cancer Res. 14, 3156-3167
 |  Abstract »  |  Full Text »  |  PDF »

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.

X. Zang, R. H. Thompson, H. A. Al-Ahmadie, A. M. Serio, V. E. Reuter, J. A. Eastham, P. T. Scardino, P. Sharma, and J. P. Allison (2007)
PNAS 104, 19458-19463
 |  Abstract »  |  Full Text »  |  PDF »

Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy.

G. Lizee, M. A. Cantu, and P. Hwu (2007)
Clin. Cancer Res. 13, 5250-5255
 |  Abstract »  |  Full Text »  |  PDF »

Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment.

T. F. Gajewski (2007)
Clin. Cancer Res. 13, 5256-5261
 |  Abstract »  |  Full Text »  |  PDF »

The B7 Family and Cancer Therapy: Costimulation and Coinhibition.

X. Zang and J. P. Allison (2007)
Clin. Cancer Res. 13, 5271-5279
 |  Abstract »  |  Full Text »  |  PDF »

A functional CD86 polymorphism associated with asthma and related allergic disorders.

T. J. Corydon, A. Haagerup, T. G. Jensen, H. G. Binderup, M. S. Petersen, K. Kaltoft, J. Vestbo, T. A. Kruse, and A. D. Borglum (2007)
J. Med. Genet. 44, 509-515
 |  Abstract »  |  Full Text »  |  PDF »

Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand.

A. Liu, A. Guardino, L. Chinsangaram, M. J. Goldstein, D. Panicali, and R. Levy (2007)
Cancer Res. 67, 7037-7044
 |  Abstract »  |  Full Text »  |  PDF »

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.

S. Loeser, K. Loser, M. S. Bijker, M. Rangachari, S. H. van der Burg, T. Wada, S. Beissert, C. J.M. Melief, and J. M. Penninger (2007)
J. Exp. Med. 204, 879-891
 |  Abstract »  |  Full Text »  |  PDF »

CD4+ T Cells in the Absence of the CD8+ Cytotoxic T Cells Are Critical and Sufficient for NKT Cell-Dependent Tumor Rejection.

C. Hong, H. Lee, M. Oh, C.-Y. Kang, S. Hong, and S.-H. Park (2006)
J. Immunol. 177, 6747-6757
 |  Abstract »  |  Full Text »  |  PDF »

CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.

M. S. von Bergwelt-Baildon, A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F. Fiore, U. Roth, M. Beyer, S. Debey, et al. (2006)
Blood 108, 228-237
 |  Abstract »  |  Full Text »  |  PDF »

Immunization with Murine Breast Cancer Cells Treated with Antisense Oligodeoxynucleotides to Type I Insulin-Like Growth Factor Receptor Induced an Antitumoral Effect Mediated by a CD8+ Response Involving Fas/Fas Ligand Cytotoxic Pathway.

R. Schillaci, M. Salatino, J. Cassataro, C. J. Proietti, G. H. Giambartolomei, M. A. Rivas, R. P. Carnevale, E. H. Charreau, and P. V. Elizalde (2006)
J. Immunol. 176, 3426-3437
 |  Abstract »  |  Full Text »  |  PDF »

Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma.

I. Tirapu, E. Huarte, C. Guiducci, A. Arina, M. Zaratiegui, O. Murillo, A. Gonzalez, C. Berasain, P. Berraondo, P. Fortes, et al. (2006)
Cancer Res. 66, 2442-2450
 |  Abstract »  |  Full Text »  |  PDF »

Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al. (2006)
Blood 107, 1332-1341
 |  Abstract »  |  Full Text »  |  PDF »

Tumor-Specific CD4+ T Cells Are Activated by "Cross-Dressed" Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines.

B. P. Dolan, K. D. Gibbs Jr., and S. Ostrand-Rosenberg (2006)
J. Immunol. 176, 1447-1455
 |  Abstract »  |  Full Text »  |  PDF »

Non-Small-Cell Lung Cancer Vaccine Therapy: A Concise Review.

D. O'Mahony, S. Kummar, and M. E. Gutierrez (2005)
J. Clin. Oncol. 23, 9022-9028
 |  Abstract »  |  Full Text »  |  PDF »

Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy.

A. Liu, P. Hu, L. A. Khawli, and A. L. Epstein (2005)
Clin. Cancer Res. 11, 8492-8502
 |  Abstract »  |  Full Text »  |  PDF »

CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion.

Y.-Q. Chen, H.-Z. Shi, X.-J. Qin, W.-N. Mo, X.-D. Liang, Z.-X. Huang, H.-B. Yang, and C. Wu (2005)
Am. J. Respir. Crit. Care Med. 172, 1434-1439
 |  Abstract »  |  Full Text »  |  PDF »

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang (2005)
Blood 106, 3515-3523
 |  Abstract »  |  Full Text »  |  PDF »

Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes.

T. P.F. Gade, W. Hassen, E. Santos, G. Gunset, A. Saudemont, M. C. Gong, R. Brentjens, X.-S. Zhong, M. Stephan, J. Stefanski, et al. (2005)
Cancer Res. 65, 9080-9088
 |  Abstract »  |  Full Text »  |  PDF »

Turning On/Off Tumor-Specific CTL Response during Progressive Tumor Growth.

Y. Huang, N. Obholzer, R. Fayad, and L. Qiao (2005)
J. Immunol. 175, 3110-3116
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma.

P. L. Triozzi, K. O. Allen, R. R. Carlisle, M. Craig, A. F. LoBuglio, and R. M. Conry (2005)
Clin. Cancer Res. 11, 4168-4175
 |  Abstract »  |  Full Text »  |  PDF »

Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12.

E. Yu. Nikitina, S. A. Desai, X. Zhao, W. Song, A. Z. Luo, R. D. Gangula, K. M. Slawin, and D. M. Spencer (2005)
Cancer Res. 65, 4309-4319
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Vaccine Based on Cell Surface Expression of DcR3/TR6.

G. Shi, J. Mao, G. Yu, J. Zhang, and J. Wu (2005)
J. Immunol. 174, 4727-4735
 |  Abstract »  |  Full Text »  |  PDF »

The Role of Intercellular Adhesion Molecule-1/LFA-1 Interactions in the Generation of Tumor-Specific CD8+ T Cell Responses.

S. R. Jenkinson, N. A. Williams, and D. J. Morgan (2005)
J. Immunol. 174, 3401-3407
 |  Abstract »  |  Full Text »  |  PDF »

Influence of CD80, Interleukin-2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expansion, Function, and Survival of Tumor-Specific CTLs.

B. Frankenberger, H. Pohla, E. Noessner, G. Willimsky, B. Papier, A. Pezzutto, J. Kopp, R. Oberneder, T. Blankenstein, and D. J. Schendel (2005)
Clin. Cancer Res. 11, 1733-1742
 |  Abstract »  |  Full Text »  |  PDF »

Engagement of NKG2D by Cognate Ligand or Antibody Alone Is Insufficient to Mediate Costimulation of Human and Mouse CD8+ T Cells.

L. I. R. Ehrlich, K. Ogasawara, J. A. Hamerman, R. Takaki, A. Zingoni, J. P. Allison, and L. L. Lanier (2005)
J. Immunol. 174, 1922-1931
 |  Abstract »  |  Full Text »  |  PDF »

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

L. J. N. Cooper, Z. Al-Kadhimi, L. M. Serrano, T. Pfeiffer, S. Olivares, A. Castro, W.-C. Chang, S. Gonzalez, D. Smith, S. J. Forman, et al. (2005)
Blood 105, 1622-1631
 |  Abstract »  |  Full Text »  |  PDF »

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

Y. Iwai, S. Terawaki, and T. Honjo (2005)
Int. Immunol. 17, 133-144
 |  Abstract »  |  Full Text »  |  PDF »

Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells.

Y. Tanaka, S. Koido, M. Ohana, C. Liu, and J. Gong (2005)
J. Immunol. 174, 1274-1280
 |  Abstract »  |  Full Text »  |  PDF »

Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells.

T. Suzuki, T. Fukuhara, M. Tanaka, A. Nakamura, K. Akiyama, T. Sakakibara, D. Koinuma, T. Kikuchi, R. Tazawa, M. Maemondo, et al. (2005)
Clin. Cancer Res. 11, 58-66
 |  Abstract »  |  Full Text »  |  PDF »

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity.

M. H. M. G. M. den Brok, R. P. M. Sutmuller, R. van der Voort, E. J. Bennink, C. G. Figdor, T. J. M. Ruers, and G. J. Adema (2004)
Cancer Res. 64, 4024-4029
 |  Abstract »  |  Full Text »  |  PDF »

Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-{gamma}-Independent Mechanisms.

X. Shi, S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma (2004)
J. Immunol. 172, 4111-4122
 |  Abstract »  |  Full Text »  |  PDF »

Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance.

M. Y. Mapara and M. Sykes (2004)
J. Clin. Oncol. 22, 1136-1151
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy.

S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg (2004)
Cancer Res. 64, 1867-1874
 |  Abstract »  |  Full Text »  |  PDF »

Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70.

C. Massa, C. Guiducci, I. Arioli, M. Parenza, M. P. Colombo, and C. Melani (2004)
Cancer Res. 64, 1502-1508
 |  Abstract »  |  Full Text »  |  PDF »

Induction of Tumor Regression by Administration of B7-Ig Fusion Proteins: Mediation by Type 2 CD8+ T Cells and Dependence on IL-4 Production.

N. Yamaguchi, S.-i. Hiraoka, T. Mukai, N. Takeuchi, X.-Y. Zhou, S. Ono, M. Kogo, K. Dunussi-Joannopoulos, V. Ling, S. Wolf, et al. (2004)
J. Immunol. 172, 1347-1354
 |  Abstract »  |  Full Text »  |  PDF »

Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity.

A. S. Lonsdorf, H. Kuekrek, B. V. Stern, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann (2003)
J. Immunol. 171, 3941-3946
 |  Abstract »  |  Full Text »  |  PDF »

B7x: A widely expressed B7 family member that inhibits T cell activation.

X. Zang, P'n. Loke, J. Kim, K. Murphy, R. Waitz, and J. P. Allison (2003)
PNAS 100, 10388-10392
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering.

K. Sandstrom, Z. Xu, G. Forsberg, and P.-A. Nygren (2003)
Protein Eng. Des. Sel. 16, 691-697
 |  Abstract »  |  Full Text »  |  PDF »

Efficacy of CD40 Ligand Gene Therapy in Malignant Mesothelioma.

P. L. Friedlander, C. L. Delaune, J. M. Abadie, M. Toups, J. LaCour, L. Marrero, Q. Zhong, and J. K. Kolls (2003)
Am. J. Respir. Cell Mol. Biol. 29, 321-330
 |  Abstract »  |  Full Text »  |  PDF »

Protection of Mice against Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia by Cell-based Vaccination Using Nonviral, Minimalistic Expression Vectors and Immunomodulatory Oligonucleotides.

J. Kochling, S. A. Konig-Merediz, R. Stripecke, D. Buchwald, A. Korte, H. G. von Einsiedel, F. Sack, G. Henze, K. Seeger, B. Wittig, et al. (2003)
Clin. Cancer Res. 9, 3142-3149
 |  Abstract »  |  Full Text »  |  PDF »

Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells.

Y. Liu, J. A. Van Ginderachter, L. Brys, P. De Baetselier, G. Raes, and A. B. Geldhof (2003)
J. Immunol. 170, 5064-5074
 |  Abstract »  |  Full Text »  |  PDF »

Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules.

M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu (2003)
J. Immunol. 170, 5317-5325
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules.

J. Briones, J. M. Timmerman, D. L. Panicalli, and R. Levy (2003)
J Natl Cancer Inst 95, 548-555
 |  Abstract »  |  Full Text »  |  PDF »

Induction of "Antigen Silencing" in Melanomas by Oncostatin M: Down-Modulation of Melanocyte Antigen Expression.

P. J. Durda, I. S. Dunn, L. B. Rose, D. Butera, E. M. Benson, F. Pandolfi, and J. T. Kurnick (2003)
Mol. Cancer Res. 1, 411-419
 |  Abstract »  |  Full Text »  |  PDF »

Prevention of Spontaneous Breast Carcinoma by Prophylactic Vaccination with Dendritic/Tumor Fusion Cells.

J. Xia, Y. Tanaka, S. Koido, C. Liu, P. Mukherjee, S. J. Gendler, and J. Gong (2003)
J. Immunol. 170, 1980-1986
 |  Abstract »  |  Full Text »  |  PDF »

GRP94 (gp96) and GRP94 N-Terminal Geldanamycin Binding Domain Elicit Tissue Nonrestricted Tumor Suppression.

J. C. Baker-LePain, M. Sarzotti, T. A. Fields, C.-Y. Li, and C. V. Nicchitta (2002)
J. Exp. Med. 196, 1447-1459
 |  Abstract »  |  Full Text »  |  PDF »

Chimeric Co-stimulatory Molecules That Selectively Act through CD28 or CTLA-4 on Human T Cells.

S. Lazetic, S. R. Leong, J. C-C. Chang, R. Ong, G. Dawes, and J. Punnonen (2002)
J. Biol. Chem. 277, 38660-38668
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of a novel metabolic strategy used by drug-resistant tumor cells.

M.-E. HARPER, A. ANTONIOU, E. VILLALOBOS-MENUEY, A. RUSSO, R. TRAUGER, M. VENDEMELIO, A. GEORGE, R. BARTHOLOMEW, D. CARLO, A. SHAIKH, et al. (2002)
FASEB J 16, 1550-1557
 |  Abstract »  |  Full Text »  |  PDF »

4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner.

R. E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and D. H. Lynch (2002)
J. Immunol. 169, 1792-1800
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Vaccines.

I. Espinoza-Delgado (2002)
Oncologist 7, 20-33
 |  Abstract »  |  Full Text »  |  PDF »

Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses exvivo.

T. L. Whiteside, A. Gambotto, A. Albers, J. Stanson, and E. P. Cohen (2002)
PNAS 99, 9415-9420
 |  Abstract »  |  Full Text »  |  PDF »

Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells.

G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner (2002)
Blood 100, 200-207
 |  Abstract »  |  Full Text »  |  PDF »

CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

G. J. D. van Mierlo, A. Th. den Boer, J. P. Medema, E. I. H. van der Voort, M. F. Fransen, R. Offringa, C. J. M. Melief, and R. E. M. Toes (2002)
PNAS 99, 5561-5566
 |  Abstract »  |  Full Text »  |  PDF »

B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.

X.-F. Bai, J. Liu, K. F. May Jr, Y. Guo, P. Zheng, and Y. Liu (2002)
Blood 99, 2880-2889
 |  Abstract »  |  Full Text »  |  PDF »

CD28 Costimulation Mediates Down-Regulation of p27kip1 and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells.

L. J. Appleman, A. A. F. L. van Puijenbroek, K. M. Shu, L. M. Nadler, and V. A. Boussiotis (2002)
J. Immunol. 168, 2729-2736
 |  Abstract »  |  Full Text »  |  PDF »

Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.

J. L. LaBelle, C. A. Hanke, B. R. Blazar, and R. L. Truitt (2002)
Blood 99, 2146-2153
 |  Abstract »  |  Full Text »  |  PDF »

Role of CD28 for the Generation and Expansion of Antigen-Specific CD8+ T Lymphocytes During Infection with Listeria monocytogenes.

H.-W. Mittrucker, M. Kursar, A. Kohler, R. Hurwitz, and S. H. E. Kaufmann (2001)
J. Immunol. 167, 5620-5627
 |  Abstract »  |  Full Text »  |  PDF »

Induction of Antitumor Immunity via Intratumoral Tetra-Costimulator Protein Transfer.

G. Zheng, A. Chen, R. E. Sterner, P. J. Zhang, T. Pan, N. Kiyatkin, and M. L. Tykocinski (2001)
Cancer Res. 61, 8127-8134
 |  Abstract »  |  Full Text »  |  PDF »

NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing Oligodeoxynucleotides.

Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, and G. J. Hammerling (2001)
J. Immunol. 167, 5247-5253
 |  Abstract »  |  Full Text »  |  PDF »

Local Costimulation Reinvigorates Tumor-Specific Cytolytic T Lymphocytes for Experimental Therapy in Mice with Large Tumor Burdens.

X.-F. Bai, J. Bender, J. Liu, H. Zhang, Y. Wang, O. Li, P. Du, P. Zheng, and Y. Liu (2001)
J. Immunol. 167, 3936-3943
 |  Abstract »  |  Full Text »  |  PDF »

Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma.

M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf (2001)
Clin. Cancer Res. 7, 2195-2204
 |  Abstract »  |  Full Text »  |  PDF »

Enhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation.

J. J. Wallin, L. Liang, A. Bakardjiev, and W. C. Sha (2001)
J. Immunol. 167, 132-139
 |  Abstract »  |  Full Text »  |  PDF »

The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma.

M. von Mehren, P. Arlen, J. Gulley, A. Rogatko, H. S. Cooper, N. J. Meropol, R. K. Alpaugh, M. Davey, S. McLaughlin, M. T. Beard, et al. (2001)
Clin. Cancer Res. 7, 1181-1191
 |  Abstract »  |  Full Text »

The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.

K. Runyon, K. Lee, K. Zuberek, M. Collins, J. P. Leonard, and K. Dunussi-Joannopoulos (2001)
Blood 97, 2420-2426
 |  Abstract »  |  Full Text »  |  PDF »

B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function.

H. Tamura, H. Dong, G. Zhu, G. L. Sica, D. B. Flies, K. Tamada, and L. Chen (2001)
Blood 97, 1809-1816
 |  Abstract »  |  Full Text »  |  PDF »

Vascular Attack by 5,6-Dimethylxanthenone-4-acetic Acid Combined with B7.1 (CD80)-mediated Immunotherapy Overcomes Immune Resistance and Leads to the Eradication of Large Tumors and Multiple Tumor Foci.

J. R. Kanwar, R. K. Kanwar, S. Pandey, L.-M. Ching, and G. W. Krissansen (2001)
Cancer Res. 61, 1948-1956
 |  Abstract »  |  Full Text »

Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation.

J. A. Kim, B. J. Averbook, K. Chambers, K. Rothchild, J. Kjaergaard, R. Papay, and S. Shu (2001)
Cancer Res. 61, 2031-2037
 |  Abstract »  |  Full Text »

Cystemustine Induces Redifferentiation of Primary Tumors and Confers Protection against Secondary Tumor Growth in a Melanoma Murine Model.

A. Demidem, D. Morvan, J. Papon, M. De Latour, and J. C. Madelmont (2001)
Cancer Res. 61, 2294-2300
 |  Abstract »  |  Full Text »

Optimal Induction of Effector but not Memory Antitumor Cytotoxic T Lymphocytes Involves Direct Antigen Presentation by the Tumor Cells.

Y. Guilloux, X.-f. Bai, X. Liu, P. Zheng, and Y. Liu (2001)
Cancer Res. 61, 1107-1112
 |  Abstract »  |  Full Text »

In Situ Expression of Soluble B7-1 in the Context of Oncolytic Herpes Simplex Virus Induces Potent Antitumor Immunity.

T. Todo, R. L. Martuza, M. J. Dallman, and S. D. Rabkin (2001)
Cancer Res. 61, 153-161
 |  Abstract »  |  Full Text »

Persistence of Immunogenic Pulmonary Metastases in the Presence of Protective Anti-melanoma Immunity.

C. K. Donawho, M. W. Pride, and M. L. Kripke (2001)
Cancer Res. 61, 215-221
 |  Abstract »  |  Full Text »

A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response.

P. R. Dunbar, C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, et al. (2000)
J. Immunol. 165, 6644-6652
 |  Abstract »  |  Full Text »  |  PDF »

Dead or Alive: Immunogenicity of Human Melanoma Cells When Presented by Dendritic Cells.

M. Shaif-Muthana, C. McIntyre, K. Sisley, I. Rennie, and A. Murray (2000)
Cancer Res. 60, 6441-6447
 |  Abstract »  |  Full Text »

Construction and Characterization of Bispecific Costimulatory Molecules Containing a Minimized CD86 (B7-2) Domain and Single-Chain Antibody Fragments for Tumor Targeting.

F. Rohrbach, B. Gerstmayer, M. Biburger, and W. Wels (2000)
Clin. Cancer Res. 6, 4314-4322
 |  Abstract »  |  Full Text »  |  PDF »

The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells.

E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn (2000)
J. Immunol. 165, 3730-3741
 |  Abstract »  |  Full Text »  |  PDF »

Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses.

R. Stripecke, A. A. Cardoso, K. A. Pepper, D. C. Skelton, X.-J. Yu, L. Mascarenhas, K. I. Weinberg, L. M. Nadler, and D. B. Kohn (2000)
Blood 96, 1317-1326
 |  Abstract »  |  Full Text »  |  PDF »

Cooperative Effects of Mycobacterium tuberculosis Ag38 Gene Transduction and Interleukin 12 in Vaccination against Spontaneous Tumor Development in Proto-neu Transgenic Mice.

L. Sfondrini, M. Rodolfo, M. Singh, M. P. Colombo, M. I. Colnaghi, S. Ménard, and A. Balsari (2000)
Cancer Res. 60, 3777-3781
 |  Abstract »  |  Full Text »

Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells.

D. K. Sojka, M. Donepudi, J. A. Bluestone, and M. B. Mokyr (2000)
J. Immunol. 164, 6230-6236
 |  Abstract »  |  Full Text »  |  PDF »

Sequential Loss of Cytotoxic T Lymphocyte Responses to Simian Virus 40 Large T Antigen Epitopes in T Antigen Transgenic Mice Developing Osteosarcomas.

T. D. Schell, B. B. Knowles, and S. S. Tevethia (2000)
Cancer Res. 60, 3002-3012
 |  Abstract »  |  Full Text »  |  PDF »

Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas.

M. von Mehren, P. Arlen, K. Y. Tsang, A. Rogatko, N. Meropol, H. S. Cooper, M. Davey, S. McLaughlin, J. Schlom, and L. M. Weiner (2000)
Clin. Cancer Res. 6, 2219-2228
 |  Abstract »  |  Full Text »

Combination Immunotherapy of Primary Prostate Cancer in a Transgenic Mouse Model Using CTLA-4 Blockade.

A. A. Hurwitz, B. A. Foster, E. D. Kwon, T. Truong, E. M. Choi, N. M. Greenberg, M. B. Burg, and J. P. Allison (2000)
Cancer Res. 60, 2444-2448
 |  Abstract »  |  Full Text »

Genetic Immunotherapy for Cancer.

A. Ribas, L. H. Butterfield, and J. S. Economou (2000)
Oncologist 5, 87-98
 |  Abstract »  |  Full Text »

The B7/CD28/CTLA4 T-Cell Activation Pathway . Implications for Inflammatory Lung Disease.

J. M. Green (2000)
Am. J. Respir. Cell Mol. Biol. 22, 261-264
 |  Full Text »

4-1BB Costimulation Is Required for Protective Anti-Viral Immunity After Peptide Vaccination.

J. T. Tan, J. K. Whitmire, K. Murali-Krishna, R. Ahmed, J. D. Altman, R. S. Mittler, A. Sette, T. C. Pearson, and C. P. Larsen (2000)
J. Immunol. 164, 2320-2325
 |  Abstract »  |  Full Text »  |  PDF »

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity.

A. D. Weinberg, M.-M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields (2000)
J. Immunol. 164, 2160-2169
 |  Abstract »  |  Full Text »  |  PDF »

Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity.

S. Salvadori, G. Martinelli, and K. Zier (2000)
J. Immunol. 164, 2214-2220
 |  Abstract »  |  Full Text »  |  PDF »

An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium.

M. Urashima, H. Suzuki, Y. Yuza, M. Akiyama, N. Ohno, and Y. Eto (2000)
Blood 95, 1258-1263
 |  Abstract »  |  Full Text »  |  PDF »

Naive CD8+ T Cells Do Not Require Costimulation for Proliferation and Differentiation into Cytotoxic Effector Cells.

B. Wang, R. Maile, R. Greenwood, E. J. Collins, and J. A. Frelinger (2000)
J. Immunol. 164, 1216-1222
 |  Abstract »  |  Full Text »  |  PDF »

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.

T. Decker, F. Schneller, T. Sparwasser, T. Tretter, G. B. Lipford, H. Wagner, and C. Peschel (2000)
Blood 95, 999-1006
 |  Abstract »  |  Full Text »  |  PDF »

Vaccination with Mouse Mammary Adenocarcinoma Cells Coexpressing B7-1 (CD80) and B7-2 (CD86) Discloses the Dominant Effect of B7-1 in the Induction of Antitumor Immunity.

A. Martin-Fontecha, M. Moro, M. C. Crosti, F. Veglia, G. Casorati, and P. Dellabona (2000)
J. Immunol. 164, 698-704
 |  Abstract »  |  Full Text »  |  PDF »

CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression.

L. J. Appleman, A. Berezovskaya, I. Grass, and V. A. Boussiotis (2000)
J. Immunol. 164, 144-151
 |  Abstract »  |  Full Text »  |  PDF »

Vaccines With Interleukin-12-Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity.

K. Dunussi-Joannopoulos, K. Runyon, J. Erickson, R. G. Schaub, R. G. Hawley, and J. P. Leonard (1999)
Blood 94, 4263-4273
 |  Abstract »  |  Full Text »  |  PDF »

Effect of Costimulation and the Microenvironment on Antigen Presentation by Leukemic Cells.

A.G.S. Buggins, N. Lea, J. Gaken, D. Darling, F. Farzaneh, G.J. Mufti, and W.J.R. Hirst (1999)
Blood 94, 3479-3490
 |  Abstract »  |  Full Text »  |  PDF »

Strong Cytotoxic T Lymphocyte Responses to a Macrophage Inflammatory Protein 1{{alpha}}-expressing Tumor: Linkage between Inflammation and Specific Immunity.

M. Maric and Y. Liu (1999)
Cancer Res. 59, 5549-5553
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products